Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.
[1]
Payne, H.; Cornford, P. Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol. Oncol., 2011, 29(6), 593-601.
[http://dx.doi.org/10.1016/j.urolonc.2009.11.003] [PMID: 20060331]
[http://dx.doi.org/10.1016/j.urolonc.2009.11.003] [PMID: 20060331]
[2]
Roehrborn, C.G. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. Int. J. Impot. Res., 2008, 20(S3)(Suppl. 3), S19-S26.
[http://dx.doi.org/10.1038/ijir.2008.53] [PMID: 19002120]
[http://dx.doi.org/10.1038/ijir.2008.53] [PMID: 19002120]
[3]
O’Shea, A.; Harisinghani, M. PI-RADS: Multiparametric MRI in prostate cancer. Magn. Reson. Mater. Biol. Phys. Med., 2022, 35(4), 523-532.
[http://dx.doi.org/10.1007/s10334-022-01019-1] [PMID: 35596009]
[http://dx.doi.org/10.1007/s10334-022-01019-1] [PMID: 35596009]
[4]
Yoneyama, T.; Tobisawa, Y.; Kaneko, T.; Kaya, T.; Hatakeyama, S.; Mori, K.; Sutoh Yoneyama, M.; Okubo, T.; Mitsuzuka, K.; Duivenvoorden, W.; Pinthus, J.H.; Hashimoto, Y.; Ito, A.; Koie, T.; Suda, Y.; Gardiner, R.A.; Ohyama, C. Clinical significance of the Lacdi NA c‐glycosylated prostate‐specific antigen assay for prostate cancer detection. Cancer Sci., 2019, 110(8), 2573-2589.
[http://dx.doi.org/10.1111/cas.14082] [PMID: 31145522]
[http://dx.doi.org/10.1111/cas.14082] [PMID: 31145522]
[5]
Ziogou, A.; Giannakodimos, A.; Giannakodimos, I. The role of urinary miRNAs in the diagnosis, management and follow-up of prostatic cancer. MicroRNA, 2023, 12(2), 83-86.
[http://dx.doi.org/10.2174/2211536612666230324102850] [PMID: 36999432]
[http://dx.doi.org/10.2174/2211536612666230324102850] [PMID: 36999432]
[6]
Giannakodimos, I. Urinary miRNAs as diagnostic biomarkers for prostatic cancer: Current dilemmas and novel potential role for a digital rectal examination. Curr. Med. Chem., 2022, 29(25), 4311-4313.
[http://dx.doi.org/10.2174/0929867329666220118101733] [PMID: 35040397]
[http://dx.doi.org/10.2174/0929867329666220118101733] [PMID: 35040397]
[7]
Paiva, R.M.; Zauli, D.A.G.; Neto, B.S.; Brum, I.S. Urinary microRNAs expression in prostate cancer diagnosis: A systematic review. Clin. Transl. Oncol., 2020, 22(11), 2061-2073.
[http://dx.doi.org/10.1007/s12094-020-02349-z] [PMID: 32323148]
[http://dx.doi.org/10.1007/s12094-020-02349-z] [PMID: 32323148]
[8]
Casanova-Salas, I.; Rubio-Briones, J.; Calatrava, A.; Mancarella, C.; Masiá, E.; Casanova, J.; Fernández-Serra, A.; Rubio, L.; Ramírez-Backhaus, M.; Armiñán, A.; Domínguez-Escrig, J.; Martínez, F.; García-Casado, Z.; Scotlandi, K.; Vicent, M.J.; López-Guerrero, J.A. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J. Urol., 2014, 192(1), 252-259.
[http://dx.doi.org/10.1016/j.juro.2014.01.107] [PMID: 24518785]
[http://dx.doi.org/10.1016/j.juro.2014.01.107] [PMID: 24518785]
[9]
Aveta, A.; Cilio, S.; Contieri, R.; Spena, G.; Napolitano, L.; Manfredi, C.; Franco, A.; Crocerossa, F.; Cerrato, C.; Ferro, M.; Del Giudice, F.; Verze, P.; Lasorsa, F.; Salonia, A.; Nair, R.; Walz, J.; Lucarelli, G.; Pandolfo, S.D. Urinary MicroRNAs as biomarkers of urological cancers: A systematic review. Int. J. Mol. Sci., 2023, 24(13), 10846.
[http://dx.doi.org/10.3390/ijms241310846] [PMID: 37446024]
[http://dx.doi.org/10.3390/ijms241310846] [PMID: 37446024]